Larry Schnurmacher, one of Phyto Partners’ cofounders has long experience in emerging markets. His venture capital fund has greatly supported 35 cannabis companies since 2015, and, with Pytho Psyche, he began investing in psychedelics-oriented companies. More investment in this sector seems to be on the way.
Schnurmacher told attendees of the inaugural Benzinga Psychedelics Capital Conference on Tuesday that he believes a new “megatrend” of neurowellness and brain health is beginning, with lots of room to invest in the psychedelics sector.
